

IIL establishes its subsidiary in NewZealand

08 December 2014 | News | By BioSpectrum Bureau

IIL establishes its subsidiary in NewZealand



Singapore: Indian vaccine major, Indian Immunologicals (IIL,) has forayed into the international market by forming a subsidiary, Pristine Biologicals, in New Zealand. The company has set up a facility to manufacture bovine serum.

Mr KV Balasubramaniam, MD, IIM said, "The overseas venture will help in strengthening in positioning ILL as a major player in foot and mouth disease (FMD) vaccine market. The \$1mn facility will help in increasing serum supplies for our vaccine manufacturing."

He added that the overseas entry will help in positioning IIL as a leader in FMD market and improve cost-competitiveness in manufacturing of veterinary and human vaccines exported to over 50 countries in the Middle East, South America, Africa and CIS countries.

The company requires 200 tons of serum, a primary requisite to produce the vaccine. The serum is obtained from disease free animals in New Zealand and Australia. "At present we completely import all the serum necessary for the vaccine. With this new facility we will be able to manufacture our own serum and become a robust player in animal vaccines with many value-added products."